Press Release: Novartis Cosentyx(R) receives FDA -2-

Novartis

134.00 EUR 0.00%

• Charts
• News
• Analysen

Kaufen Verkaufen

https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials

[Last accessed: February 2026].

11. Novartis Cosentyx receives FDA approval for the treatment of children and

adolescents with enthesitis-related arthritis and psoriatic arthritis.

[Press release]. Available

at: https://www.novartis.com/news/media-releases/novartis-cosentyx-receiv

es-fda-approval-treatment-children-and-adolescents-enthesitis-related-art

hritis-and-psoriatic-arthritis [Last accessed: February 2026].

12. Novartis Cosentyx receives positive CHMP opinion for expanded use in

childhood arthritic conditions. [Press release]. Available

at: https://www.novartis.com/news/media-releases/novartis-cosentyx-secuki

numab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-con

ditions [Last accessed: February 2026].

13. Data on file. Cosentyx WW LTD patients Q1'25.

14. Uta Kiltz et al. Secukinumab Retention and Effectiveness in Patients with

PsA and Radiographic Axial Spondyloarthritis: 5-year Final Results of a

Prospective Real-world Study. Abstract no:2344. ACR 2024 [Link

https://acrabstracts.org/abstract/secukinumab-retention-and-effectiveness-in-patients-with-psoriatic-arthritis-and-radiographic-axial-spondyloarthritis-5-year-final-results-of-a-prospective-real-world-study/

]

15. Ippoliti et al. Long-Term Real-World Safety Profile

of Secukinumab Assessed Through a 9-Year Experience in Patients Affected

by Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis:

Results From a Multicentric Retrospective Study. Dermatologic Therapy.

2025. Article Number: 9618241 [Link

https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9618241 ]

16. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P,

Pascale P, Delicha EM, Pricop L, Mpofu S. "Secukinumab Provides Sustained

Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final

5Year Efficacy and Safety Results from a Phase 3 Trial". ACR/ARHP 2020

Annual Meeting Abstract. Presented in ACR Open Rheumatology (2020);

CONCL00511 (Secukinumab Provides Sustained Improvements in the Signs and

Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3

FUTURE 1 Study - PubMed)

17. McInnes IB, Mease PJ, Kivitz AJ, Nash P, Rahman P, Rech J, Conaghan PG,

Kirkham B, Navarra S, Belsare AD, Delicha EM, Pricop L, Mpofu S; FUTURE 2

Study Group. "Longterm efficacy and safety of secukinumab in patients

with psoriatic arthritis: 5year (endofstudy) results from the phase III

FUTURE 2 study." Lancet Rheumatology. 2020; 2(4): e227--e235. (Long-term

efficacy and safety of secukinumab in patients with psoriatic arthritis:

5-year (end-of-study) results from the phase 3 FUTURE 2 study)

18. Bissonnette R, Luger T, Thaçi D, Toth D, Lacombe A, Xia S, Mazur R,

Patekar M, Charef P, Milutinovic M, Leonardi C,

Mrowietz U.Secukinumab demonstrates high sustained efficacy and

a favourable safety profile in patients with moderate-to-severe psoriasis

through 5 years of treatment (SCULPTURE Extension

Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507--1514.

(Secukinumab demonstrates high sustained efficacy and a favourable safety

profile in patients with moderate-to-severe psoriasis through 5 years of

treatment (SCULPTURE Extension Study) - PubMed)

19. Garg A, Naik HB, Alavi A, et al. Real-World Findings on

the Characteristics and Treatment Exposures of Patients with Hidradenitis

Suppurativa from US Claims Data. Dermatol Ther (Heidelb). 2023

Feb;13(2):581-594. doi: 10.1007/s13555-022-00872-1.

20. Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis Suppurativa. Nat

Rev Dis Primers. 2020;6 18. doi: 10.1038/s41572-020-0149-1.

21. Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed Diagnosis of

Hidradenitis Suppurativa and Its Effect on Patients and Healthcare

System. Dermatology. 2020;236(5):421-430. doi: 10.1159/000508787

22. Mac Mahon J, Kirthi S, Byrne N, et al. An Update on Health-Related

Quality of Life and Patient-Reported Outcomes in Hidradenitis

Suppurativa. Patient Relat Outcome Meas. 2020;11:21-26. doi:

10.2147/PROM.S174299.

23. Montero-Vílchez T, Sánchez-Díaz M,

Martínez-López A, et al. Quality of Life in Patients with Skin

Disease and Their Cohabitants. In: Jasneth M, Sage A, Medhane C, Eds.

Health-Related Quality of Life. Rijeka: IntechOpen; 2021: Ch. 5.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41

61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

March 13, 2026 13:35 ET (17:35 GMT)